Cilia and flagella associated protein 81 (DLEC1): A Potential Drug Target and Biomarker

Target Name: DLEC1

NCBI ID: G9940

DLEC1

Cilia and flagella associated protein 81 (DLEC1): A Potential Drug Target and Biomarker

Cilia and flagella associated protein 81 (DLEC1) is a protein that plays a crucial role in the function of cilia and flagella, which are essential organelles found in many eukaryotic cells. DLEC1 is a 21-kDa protein that is expressed in various cell types, including epithelial, endothelial, and muscle cells. It is composed of two distinct subunits, DLEC1-A and DLEC1-B, which are responsible for the protein's unique structure and function.

The Role of DLEC1 in Cilia and Flagella

Cilia and flagella are small structures that are composed of repetitive, linear protein molecules that are responsible for the movement of cells. These structures are composed of a series of helical filaments that are bundled together and covered with a thin layer of lipid. When cells are activated, the cilia and flagella proteins unfurl from their cytoplasmic environment, allowing the cell to move in various directions.

DLEC1 is involved in the regulation of cilia and flagella function. It plays a critical role in the structure and stability of these organelles. DLEC1-A is responsible for the formation of the cilia, while DLEC1-B is involved in the regulation of cilia stability.

DLEC1-A is the protein that is targeted by many drugs, including those used to treat various diseases, such as cancer, heart failure, and neurodegenerative disorders. The mechanism of action of these drugs is based on their ability to inhibit the activity of DLEC1-A, leading to the collapse of the cilia and the loss of cell movement.

DLEC1-B is also a potential drug target. The inhibition of DLEC1-B has been shown to be effective in various models of cancer, including the inhibition of cell migration and the inhibition of tumor growth.

DLEC1 as a Biomarker

DLEC1 has also been shown to be a potential biomarker for various diseases. For example, the levels of DLEC1 have been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. This increase in DLEC1 has been associated with the development and progression of these diseases.

In addition, DLEC1 has also been shown to be elevated in various cardiovascular diseases, including heart failure and hypertension. The increased DLEC1 levels have been associated with the worsening of these conditions.

Molecular Mechanisms

The molecular mechanisms underlying the regulation of DLEC1-A and DLEC1-B are not well understood. However, several studies have shown that DLEC1 is involved in various signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway.

The TGF-β pathway is involved in the regulation of cell growth, differentiation, and survival. DLEC1 has been shown to be involved in the regulation of TGF-β signaling, with several studies showing that DLEC1 inhibits the activity of the TGF-β receptor.

The PI3K/Akt pathway is involved in the regulation of cell signaling, including the regulation of cell growth and the regulation of cell survival. DLEC1 has also been shown to be involved in the regulation of PI3K/Akt signaling, with several studies showing that DLEC1 inhibits the activity of the PI3K/Akt kinase.

DLEC1 Interference with Drug Development

The inhibition of DLEC1 has been shown to be an effective strategy for the development of drugs that target various diseases, including cancer, heart failure, and neurodegenerative disorders. Many of these drugs work by inhibiting the activity of DLEC1-A or DLEC1-B, leading to the collapse of the cilia and the loss of

Protein Name: DLEC1 Cilia And Flagella Associated Protein

Functions: Essential for spermatogenesis and male fertility (By similarity). May play an important role in sperm head and tail formation (By similarity). May act as a tumor suppressor by inhibiting cell proliferation

The "DLEC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLEC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets